- Home
- ALT vs IDR Comparison
ALT vs IDR Comparison
Compare ALT & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | IDR |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 378.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALT | IDR |
|---|---|---|
| Price | $3.61 | $39.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $16.33 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 4.8M | 676.6K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.70 |
| EPS | N/A | ★ 0.73 |
| Revenue | $20,000.00 | ★ $35,424,313.00 |
| Revenue This Year | N/A | $55.62 |
| Revenue Next Year | N/A | $23.93 |
| P/E Ratio | ★ N/A | $55.52 |
| Revenue Growth | N/A | ★ 61.35 |
| 52 Week Low | $2.90 | $9.90 |
| 52 Week High | $7.83 | $54.70 |
Technical Indicators
Market Signals| Indicator | ALT | IDR |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 47.18 |
| Support Level | $3.83 | $41.65 |
| Resistance Level | $5.37 | $48.75 |
| Average True Range (ATR) | 0.32 | 3.46 |
| MACD | -0.18 | -0.57 |
| Stochastic Oscillator | 2.39 | 9.29 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.